论文部分内容阅读
目的 :探讨内芯降温射频治疗仪 (CRF)治疗肝肿瘤的适应症、疗效及其对机体免疫力的影响。方法 :应用 CRF治疗 2 0例肝肿瘤 ,观察治疗前及治疗后 10~ 14天、1月患者肝功能、外周血血清肿瘤标志物、CD4+ 、CD8+ 、CD4+ / CD8+、病灶大小及回声、病灶内血流、病灶在增强 CT/ MRI上的改变。结果 :治疗后 2 7个病灶完全坏死表现为肿瘤体积缩小 ,整个病灶回声增强 ,病灶内检测不出血流信号 ,肿瘤标志物下降明显甚至下降至正常 ;5个病灶部分坏死表现为只有部分病灶回声增强 ,病灶内检测不出血流信号或血流信号减少 ,肿瘤标志物下降不明显或不下降。所有患者治疗后 CD4+值升高、CD4+ / CD8+比值升高。结论 :对于小于 3.6 cm的肝肿瘤 CRF射频消融可一次性全部灭活 ,对于 3.6 cm以上的肝肿瘤需多次射频消融 ,射频消融在杀灭治疗肿瘤的同时可改善患者的免疫状态
Objective : To investigate the indications, curative effect and its effect on the immunity of the patients with liver tumors treated with CRF. Methods: Twenty patients with liver tumors were treated with CRF. Liver function, serum tumor markers, CD4+, CD8+, CD4+/CD8+, lesion size, echo, and lesions before and 10 to 14 days after treatment, 1 month after treatment were observed. Changes in blood flow and lesions on enhanced CT/MRI. RESULTS: After treatment, complete necrosis of 27 lesions showed that the tumor volume was reduced, the echo of the entire lesion was enhanced, no intra-lesional flow signal was detected, tumor markers decreased significantly or even decreased to normal; partial necrosis of 5 lesions showed only partial lesions. Echo enhancement, detection of no intra-lesional blood flow signal or blood flow signal reduction, tumor markers decreased significantly or not. All patients had elevated CD4+ and increased CD4+/CD8+ ratio after treatment. Conclusion : Radiofrequency ablation of liver tumors less than 3.6 cm in diameter can be inactivated all at once. Radiofrequency ablation is required for liver tumors above 3.6 cm. Radiofrequency ablation can improve the patient’s immune status while killing and treating tumors.